This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A look at Relmada Therapeutics' novel NMDAR channel blocker, REL-1017, as monotherapy for the treatment of MDD and its P2 data
Ticker(s): RLMDWho's the expert?
Institution: ULP
- Practices in a variety of psychiatric settings including; standalone psychiatric emergency departments, inpatient units, hospital consultant services, and outpatient services
- treats approximately 20-30 patients with MDD per month on an outpatient basis and approximately 100-120 per month on an inpatient basis.
- Academic interests include mood disorders, psychosis, and personality disorders, suicide, feigned behaviors, and severe mental illness
Interview GoalDiscussing the potential of REL-1017, Relmada Therapeutics' novel NMDAR channel blocker, as monotherapy for the treatment of MDD and reviewing the published Phase 2a data for REL-1017 as adjunctive treatment in MDD.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
